Azitra has been awarded a $225,000 Small Business Innovation Research award from the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health.

The grant will support development of Azitra’s skin microbiome therapeutic, AZT-02, a Live Biotherapeutic Product for treatment of Netherton Syndrome, a severely disabling orphan skin disease.

Azitra’s Chief Scientific Officer, Travis Whitfill, and The Jackson Laboratory’s skin microbiome expert, Julia Oh, are the principal investigators on this grant.